# Immunotherapy and Paraneoplastic Neurological Syndromes

> **NCT02343211** · PHASE2 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 17 (estimated)

## Conditions studied

- Paraneoplastic Neurological Syndromes

## Interventions

- **DRUG:** Immunoglobulin

## Key facts

- **NCT ID:** NCT02343211
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2016-06
- **Final completion:** 2016-12
- **Target enrollment:** 17 (ESTIMATED)
- **Last updated:** 2017-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02343211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02343211, "Immunotherapy and Paraneoplastic Neurological Syndromes". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02343211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*